(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 3.9% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Becton Dickinson & Co's revenue in 2025 is $21,386,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,263,231,540,029, with the lowest BDX revenue forecast at $6,250,823,436,896, and the highest BDX revenue forecast at $6,276,717,362,446. On average, 8 Wall Street analysts forecast BDX's revenue for 2026 to be $6,572,072,064,622, with the lowest BDX revenue forecast at $6,520,488,292,281, and the highest BDX revenue forecast at $6,643,451,476,482.
In 2027, BDX is forecast to generate $6,874,826,628,165 in revenue, with the lowest revenue forecast at $6,781,892,544,009 and the highest revenue forecast at $6,944,696,946,401.